Entelos Announces DrugMatrix Perpetual License Agreement with Lilly

Entelos Inc.

ENTELOS, Inc.

("Entelos" or "the Company")

Entelos, Inc. (LSE:ENTL), a leading life sciences company applying predictive
technologies and "virtual humans" to find better drugs and more tailored
health-related products announced today that Eli Lilly and Company ("Lilly") has
exercised its right to a perpetual license to Entelos' DrugMatrix(R) database
and additional customized report services from ToxFx(TM). Lilly will make a
one-time payment to Entelos for a perpetual license and has the option for
continued support. Financial terms were not disclosed.

"We are pleased that Lilly exercised its option to obtain a perpetual license to
our powerful toxicogenomics database, customized reports, and safety reference
systems," commented James Karis, President and CEO of Entelos. "We look forward
to continuing our support of Lilly and helping them to accelerate their adoption
and integration of our cutting-edge predictive technologies within their
research organization."

The DrugMatrix database is a unique reference set of gene expression profiles
for benchmark drugs and compounds that are linked to classic pharmacology,
toxicology and clinical pathology measurements. It is populated with the
comprehensive results of thousands of highly controlled and standardized
experiments used to test for drug safety.

Profiles from over 630 different compounds from FDA approved drugs, drugs
approved in Europe and Japan, withdrawn drugs, drugs in preclinical and clinical
studies, biochemical standards and industrial and environmental toxicants are
contained in DrugMatrix. Entelos customers using DrugMatrix can thus predict
safety and toxicity liabilities of novel molecules using much shorter, faster,
and more cost-effective gene expression studies as compared to traditional
methods.

For further information please contact:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations Tel: +1 650 572 5400

KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson Tel +44 (0) 20 4718 8900

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson Tel +44 (0) 20 7466 5000

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual human" technology, and toxicology reference
systems to develop safer and more effective drugs, improve the quality of
health-related consumer products, and deliver on the promise of personalized
medicine. Entelos provides customized products, technology and research services
to global pharmaceutical, health-care, and consumer products companies in safety
testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes,
hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal
care products.

Entelos Regs (LSE:ENTL)
過去株価チャート
から 5 2024 まで 6 2024